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Envenomations by the brown recluse spider, Loxosceles reclusa, are a significant 
source of morbidity and occasional mortality in endemic regions of the United States, 
and misdiagnoses are common.  A survey of physicians in the endemic area has shown 
the economic viability of an accurate diagnostic test for these spider bites.  Development 
and testing of an optimized loxosceles venom test kit will present significant challenges.  
Unlike the routine construction of ELISAs dedicated to the detection of a single protein, 
the proposed kit immunoassay will detect venom containing multiple proteins, including a 
unique physiologically active protein-sphingomyelinase D (SMD) abundantly present in 
the venom.  In preliminary and Phase I research, our polyclonal assay has shown good 
in-vitro and in-vivo sensitivity and specificity.  Our research shows that identifiable 
amounts of venom in clinical envenomations persist for at least 5 days, our longest 
probable envenomation, which covers the majority of cases encountered in emergency 
rooms and clinics.  Phase I testing showed high specificity, with none of 60 competing 
inflammatory diagnoses showing reactivity above background.   
  
The limits of sensitivity, in-vivo specificity, and the duration of detection of the recently 
developed venom-affinity purified test are unknown.  Phase I development of a venom-
affinity purified polyclonal assay has successfully allowed several orders of magnitude 
increase in sensitivity above that of other assays.  Remarkably, the current swab test 
now operates in the femtogram range (one billionth of a microgram).   This allows 
detection of venom even after the victim has washed the suspected bite site.  Phase I 
analysis determined that monoclonal antibodies raised in a bioreactor had relatively 
weak venom affinity and provided no improvement over the polyclonal antibody-based 
assay.  If conjugated monoclonal techniques fail in Phase II, then the assay will use only 
polyclonal antibodies in an optimized microtiter plate assay.   A prototype microtiter 
colorimetric assay is now available and ready for testing by hospitals with ELISA reader 
capability.  A simplified tube kit test or other format developed during Phase II will allow 
testing by small hospitals.  These clinical studies will allow determination of sensitivity 
and specificity of our test, with the goal of FDA device approval and ultimately marketing.  
Clinical application of an optimized assay would save the morbidity and expense due to 
inappropriate diagnosis and treatment of various skin conditions with presentations 
similar to Loxosceles envenomations.  Techniques used in the successful detection of 
this spider venom are directly applicable to bites from S. American Loxosceles species, 
which are responsible for additional deaths each year.  The swab venom assay 
technique could be applicable to envenomations by spiders outside the Loxosceles 
genus. 
 
